|
O.S. Elsukova, E.A. Nikitina
Efficiency of a fixed combination of insulin glargine and lixisenatide in everyday clinical practice
|
№2 / 2025
|
|
M.B. Antsiferov
CLINICAL CHARACTERISTICS AND PRACTICAL ASPECTS OF THE USE OF NEW BASAL INSULIN GLARGINE 300 U/ ML TOUJEO SOLOSTAR®
|
№16 / 2016
|
|
I.V. Glinkina
ORIGIN STUDY (OUTCOME REDUCTION WITH INITIAL GLARGINE INTERVENTION) 2 YEARS LATER: WHAT’S NEW?
|
№16 / 2014
|
|
N.A. Chernikova 1, A.S. Ametov 1, M.B. Antsiferov 2
BASAL INSULIN THERAPY: EXPERIENCE IN CLINICAL PRACTICE
|
№16 / 2013
|
|
M.B. Antsiferov 1, E.V. Biryukova 2 , A.V. Zilov 3
Early Use Of Insulin Glargine In Patients With Type 2 Diabetes Mellitus, Pre-diabetes And High Cardiovascular Risk: Results Of Origin Study
|
№16 / 2012
|
|
N. A. Chernikova, M.A. Prudnikova
Timely Administration Of Insulin Therapy In Type 2 Diabetes Mellitus
|
№3 / 2012
|
|
Glinkina I.V., Romancova T.I.
Results Of Observational Program On Use Of Insulin Glargine (lantus®) In Combination With Oral Hypoglycemic Agents For The Treatment Of Type 2 Diabetes Mellitus In Routine Clinical Practice
|
№3 / 2011
|
|
M.Antsiferov С. 1621
Use Of Long-acting Insulin Analogues In Type 2 Diabetes Mellitus Treatment (according To The Data Of International And Russian Registries)
|
№3 / 2010
|
Русский
